Aida Fiz-López

Mrs. Aida Fiz-López

Universidad de Valladolid
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Albert MoralesAlbert Morales
Albert Morales
SRSilvia Rojo Rello
Silvia Rojo Rello
HCHelena Cristóbal
Helena Cristóbal
Aida Fiz-LópezAida Fiz-López
Aida Fiz-López
ERElisa Arribas Rodríguez
Elisa Arribas Rodríguez
Pablo García de FrutosPablo García de Frutos
Pablo García de Frutos
Background: Growth arrest-specific factor 6 (GAS6) and the Tyro3, AXL, and MERTK (TAM) receptors counterbalance pro-inflammatory responses. AXL is a candidate receptor for SARS-CoV-2, particularly in the respiratory system, and the GAS6/AXL axis is targeted in current clinical trials against COVID-19. However, GAS6 and TAMs have not been evaluated in COVID-19 patients at emergency admission. Methods: Plasma GAS6, AXL, and MERTK were analyzed in 132 patients consecutively admitted to the emergency ward during the first peak of COVID-19. Results: GAS6 levels were higher in the SARS-CoV-2-positive patients, increasing progressively with the severity of the disease. Patients with initial GAS6 at the highest quartile had the worst outcome, with a 3-month survival of 65%, compared to a 90% survival for the rest. Soluble AXL exhibited higher plasma concentration in deceased patients, without significant differences in MERTK among SARS-CoV-2-positive groups. GAS6 mRNA was mainly expressed in alveolar cells and AXL in airway macrophages. Remarkably, THP-1 human macrophage differentiation neatly induces AXL, and its inhibition (bemcentinib) reduced cytokine production in human macrophages after LPS challenge. Conclusions: Plasma GAS6 and AXL levels reflect COVID-19 severity and could be early markers of disease prognosis, supporting a relevant role of the GAS6/AXL system in the immune response in COVID-19.

Verified
Journal Article
Open access
PDF file
AVAlvaro Tamayo Velasco
Alvaro Tamayo Velasco
MPMaría Jesús Peñarrubia-Ponce
María Jesús Peñarrubia-Ponce
F. JAVIER ALVAREZF. JAVIER ALVAREZ
F. JAVIER ALVAREZ
HGHugo Gonzalo
Hugo Gonzalo
IGIGNACIO DE LA FUENTE GRACIANI
IGNACIO DE LA FUENTE GRACIANI
EGEsther Gómez-Sánchez
Esther Gómez-Sánchez
Antigen tests or polymerase chain reaction (PCR) amplification are currently COVID-19 diagnostic tools. However, developing complementary diagnosis tools is mandatory. Thus, we performed a plasma cytokine array in COVID-19 patients to identify novel diagnostic biomarkers. A discovery–validation study in two independent prospective cohorts was performed. The discovery cohort included 136 COVID-19 and non-COVID-19 patients recruited consecutively from 24 March to 11 April 2020. Forty-five cytokines’ quantification by the MAGPIX system (Luminex Corp., Austin, TX, USA) was performed in plasma samples. The validation cohort included 117 patients recruited consecutively from 15 to 25 April 2020 for validating results by ELISA. COVID-19 patients showed different levels of multiple cytokines compared to non-COVID-19 patients. A single chemokine, IP-10, accurately identified COVID-19 patients who required hospital admission (AUC: 0.962; 95%CI (0.933–0.992); p < 0.001)). The results were validated in an independent cohort by multivariable analysis (OR: 25.573; 95%CI (8.127–80.469); p < 0.001) and AUROC (AUC: 0.900; 95%CI (0.846–0.954); p < 0.001). Moreover, showing IP-10 plasma levels over 173.35 pg/mL identified COVID-19 with higher sensitivity (86.20%) than the first SARS-CoV-2 PCR. Our discover–validation study identified IP-10 as a robust biomarker in clinical practice for COVID-19 diagnosis at hospital. Therefore, IP-10 could be used as a complementary tool in clinical practice, especially in emergency departments.

Verified
Journal Article
Open access
PDF file
Carlos Manuel González-CasimiroCarlos Manuel González-Casimiro
Carlos Manuel González-Casimiro
ERElisa Arribas Rodríguez
Elisa Arribas Rodríguez
Aida Fiz-LópezAida Fiz-López
Aida Fiz-López
JCJavier Casas
Javier Casas
SGSara Gutiérrez González
Sara Gutiérrez González
German PerdomoGerman Perdomo
German Perdomo
Although the COVID-19 disease has developed into a worldwide pandemic, its pathophysiology remains to be fully understood. Insulin-degrading enzyme (IDE), a zinc-metalloprotease with a high affinity for insulin, has been found in the interactomes of multiple SARS-CoV-2 proteins. However, the relevance of IDE in the innate and adaptative immune responses elicited by circulating peripheral blood mononuclear cells is unknown. Here, we show that IDE is highly expressed on the surface of circulating monocytes, T-cells (both CD4+ and CD4−), and, to a lower extent, in B-cells from healthy controls. Notably, IDE’s surface expression was upregulated on monocytes from COVID-19 patients at diagnosis, and it was increased in more severe patients. However, IDE’s surface expression was downregulated (relative to healthy controls) 3 months after hospital discharge in all the studied immune subsets, with this effect being more pronounced in males than in females, and thus it was sex-dependent. Additionally, IDE levels in monocytes, CD4+ T-cells, and CD4− T-cells were inversely correlated with circulating insulin levels in COVID-19 patients (both at diagnosis and after hospital discharge). Of note, high glucose and insulin levels downregulated IDE surface expression by ~30% in the monocytes isolated from healthy donors, without affecting its expression in CD4+ T-cells and CD4− T-cells. In conclusion, our studies reveal the sex- and metabolism-dependent regulation of IDE in monocytes, suggesting that its regulation might be important for the recruitment of immune cells to the site of infection, as well as for glucometabolic control, in COVID-19 patients.

29 August 2024 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
Aida Fiz-LópezAida Fiz-López
Aida Fiz-López
ÁPÁngel De Prado
Ángel De Prado
EAElisa Arribas‐Rodríguez
Elisa Arribas‐Rodríguez
FGFrancisco Javier García‐Alonso
Francisco Javier García‐Alonso
SISandra Izquierdo
Sandra Izquierdo
DBDavid Bernardo
David Bernardo
Background: Intraepithelial lymphocytes are the first line of defence of the human intestinal immune system. Besides, their composition is altered on patients with coeliac disease (CD), so they are considered as biomarkers with utility on their diagnose and/or monitoring. Our aim is to address their variability through the human gastrointestinal tract in health and characterized them in further depth in the coeliac duodenum.Methods: Intraepithelial lymphocytes were isolated from human gastric, duodenal, ileal and colonic biopsies, then stained with specific antibodies and acquired by flow cytometry.Results: Our results confirmed that the profile of Intraepithelial lymphocytes change through the length of the human gastrointestinal tract. Besides and given the central role that Interleukin‐15 (IL‐15) elicits on CD pathogenesis; we also assessed the expression of its receptor revealing that there was virtually no functional IL‐15 receptor on duodenal Intraepithelial lymphocytes. Nevertheless and contrary to our expectations, the active IL‐15 receptor was not increased either on Intraepithelial lymphocytes from CD patients.Conclusions: IL‐15 might require additional stimulus to activate intraepithelial lymphocytes. These findings may provide novel tools to aid on a CD diagnosis and/or monitoring, at the time that provide the bases to perform functional studies in order of getting a deeper insight in the specific function that Intraepithelial lymphocytes elicit on CD pathogenesis.

17 March 2026 in Journal of Infection
Verified
Journal Article
Open access
MMMarina Perez Mazzali
Marina Perez Mazzali
FPFrancisco Perez
Francisco Perez
PCPaloma Cal-Sabater
Paloma Cal-Sabater
PRPaulina Rybakowska
Paulina Rybakowska
PTPablo Tellería
Pablo Tellería
SCSara Cuesta-Sancho
Sara Cuesta-Sancho
Long COVID is a complex condition characterized by a broad spectrum of persistent, multisystemic symptoms that often impair daily activities and cause disability with significant socioeconomic impact. Although several hypotheses have been proposed to explain its pathophysiology-including immune dysregulation-the underlying mechanisms remain poorly understood. Indeed, there are no current treatments for this condition. Therefore, we aimed to characterize immune alterations induced by SARS-CoV-2 during the acute phase of infection and three months post-hospital discharge in a cohort of patients who later developed Long COVID, referred to a matched cohort who did not. We performed high-dimensional immune profiling of peripheral blood mononuclear cells using a 40-marker mass cytometry panel. Data analysis combined classical hierarchical gating strategies with unsupervised computational approaches. Our results revealed distinct immune signatures between Long COVID and non-Long COVID patients, affecting both the innate and adaptive immune compartments. Notably, individuals who subsequently developed Long COVID exhibited early abnormalities at infection in innate immunity, particularly involving dendritic cells and γδ T cells. Moreover, three months post-discharge, persistent alterations were observed in several adaptive immune cell subsets in patients who next developed Long COVID over time. In summary, our findings suggest that early immune dysregulation following viral infection may predispose individuals to persistent post-viral pathology.

24 February 2026 in European Journal of Immunology
Verified
Journal Article
Open access
ERElisa Arribas Rodríguez
Elisa Arribas Rodríguez
CCCarolina G. de Castro
Carolina G. de Castro
Aida Fiz-LópezAida Fiz-López
Aida Fiz-López
ÁPÁngel De Prado
Ángel De Prado
ÁMÁlvaro Martín‐Muñoz
Álvaro Martín‐Muñoz
DBDavid Bernardo
David Bernardo
This study aimed to characterize human intestinal conventional dendritic cells (cDCs) in health and inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). Three cDC subsets (CD103 − cDC2, CD103 + cDC2, and cDC1) were identified from lamina propria mononuclear cells. Their phenotype and function were analyzed in healthy and IBD‐inflamed gut tissues. In the healthy gut, cDC2 predominated over cDC1, with CD103 + cDC2 dominating the duodenum and CD103 − cDC2 prevalent in the ileum and colon. CD103 + cDC2 expressed higher PD‐L1 and produced more IL‐10. In culture, CD103 + cDC2 increased proportionally unless inhibited by LPS. All subsets induced IL‐10 + helper T‐cell differentiation, with ileal cDCs being more stimulatory than colonic ones. In IBD, cDCs showed constitutively lower SIRPα expression across conditions. Notably, UC‐inflamed colon exhibited reduced cDC1 and CD103 + cDC2, while CD‐inflamed colon maintained these subsets but showed increased T‐cell stimulation and IL‐17 + T‐cell priming. Intestinal cDC subsets prime IL‐10 + helper T‐cells in health. In UC, reduced cDC1 and CD103 + cDC2 in inflamed mucosa contrast with CD, suggesting distinct pathogenic mechanisms that could inform targeted therapies.